Eli Lilly and Company
) Cyramza (ramucirumab) showed improved overall survival rate
compared to chemotherapy alone in patients suffering from
second-line non-small cell lung cancer (NSCLC) in a global phase
III study (REVEL). The company announced detailed results from the
REVEL study (n=1253) at the American Society of Clinical Oncology
(ASCO) Annual Meeting.
The randomized, double-blind study compared the combination of
) Taxotere (docetaxel) to Taxotere and placebo in second-line
nonsquamous and squamous NSCLC patients whose disease progressed
after platinum-based chemotherapy for locally-advanced or
In this study, Cyramza showed a statistically significant
improvement across multiple efficacy endpoints including overall
survival, progression-free survival and overall response rate.
Patients treated with Cyramza plus Taxotere showed nearly 14% and
24% reduction in risk of death and risk of progression or death,
We remind investors that Eli Lilly had first announced positive
data from the phase III REVEL study on Cyramza in Feb 2014.
Eli Lilly plans to submit regulatory applications for Cyramza based
on data from the REVEL study in the second half of 2014.
We note that Cyramza is already approved as a single-agent
treatment for patients suffering from advanced or metastatic
gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma
with disease progression following prior fluoropyrimidine- or
platinum-containing chemotherapy. The drug has orphan drug status
in the U.S. for this indication.
Eli Lilly is also evaluating Cyramza for other types of cancer
including liver and colorectal cancer. Eli Lilly intends to file
for approval of Cyramza in combination with Taxol for patients
suffering from gastric cancer in 2014.
The biggest near-term challenge for Eli Lilly is to replace the
revenues lost due to the genericization of Zyprexa, Cymbalta and
Evista. We are encouraged by the positive data from the REVEL study
on Cyramza. Cyramza's approval for additional indications will
boost Eli Lilly's revenues.
Eli Lilly carries a Zacks Rank #3 (Hold). Some better-ranked stocks
in the health care sector include
ANI Pharmaceuticals, Inc.
). Both stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis
ANI PHARMACEUT (ANIP): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
To read this article on Zacks.com click here.